Evenity (Romosozumab) and Imaging Contrast Dye: What You Need to Know Before Your Scan

Does Evenity Interact with Contrast Dye?

No direct pharmacokinetic or pharmacodynamic interaction between romosozumab and imaging contrast agents has been identified in published literature or in the FDA-approved prescribing information. Romosozumab is a large monoclonal antibody with a molecular weight of approximately 136 kDa; it is metabolized via proteolytic catabolism, not by hepatic cytochrome P450 enzymes, and it is not renally cleared in the same way small-molecule drugs are. Iodinated contrast agents and gadolinium-based contrast agents (GBCAs) work through entirely different mechanisms and are eliminated primarily by the kidneys within hours of administration.

Because these two drug classes operate through completely separate biological pathways, a true drug-drug interaction in the classical sense is not expected and has not been reported in the FDA label for Evenity.

Contrast imaging while on any bone-active therapy raises several practical clinical questions that deserve direct answers.

Why the Question Comes Up

Women on Evenity are typically being monitored for osteoporosis progression. That monitoring often includes bone density imaging (DEXA), but sometimes includes CT scans of the spine or pelvis, MRI for vertebral fracture assessment, or nuclear medicine bone scans. Contrast is frequently requested alongside these studies. Your radiologist needs your full medication list, and Evenity should be on it, not because it interacts with contrast dye directly, but because:

1. Monoclonal antibody therapies can occasionally affect renal biomarkers in complex ways, and renal function is the central safety variable for contrast administration.
2. The imaging findings themselves, such as bone density changes, periosteal new bone formation, and vertebral end-plate changes, can look unusual on CT or MRI after bone-active therapy and need radiological context.
3. Rare but serious adverse events associated with Evenity (cardiovascular events, osteonecrosis of the jaw, atypical femoral fractures) may be relevant to interpretation of imaging findings.

What the Prescribing Label Actually Says

The FDA prescribing information for romosozumab does not list iodinated contrast or gadolinium agents in its drug-interactions section. The label identifies no cytochrome P450-mediated interactions, no transporter-mediated interactions, and no interactions with calcium, vitamin D, bisphosphonates, or other bone agents that would be expected to amplify contrast nephrotoxicity.

Contrast Dye Safety: What Matters Most Is Your Kidney Function, Not Romosozumab

The primary safety concern with contrast imaging is contrast-induced nephropathy (CIN) or, more precisely, post-contrast acute kidney injury (PC-AKI). The American College of Radiology Manual on Contrast Media (ACR, updated 2023) notes that PC-AKI risk is meaningful in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m² for iodinated contrast, and below 30 mL/min/1.73m² for most gadolinium agents (with nephrogenic systemic fibrosis risk at eGFR <30).

Romosozumab itself is not nephrotoxic, and the FRAME trial, the key phase 3 placebo-controlled study of romosozumab in 7,180 postmenopausal women, reported no significant difference in renal adverse events between the romosozumab and placebo groups over 12 months. The trial used subcutaneous romosozumab 210 mg monthly, the same dose used clinically.

eGFR Thresholds That Matter

| Contrast type | eGFR threshold for routine use | eGFR threshold for elevated caution | |---|---|---| | Iodinated CT contrast (IV) | eGFR ≥30 generally safe | eGFR <30: increased PC-AKI risk | | Gadolinium MRI contrast (Group II/III GBCAs) | eGFR ≥30 for most agents | eGFR <30: NSF risk, use Group I only or avoid | | Oral iodinated contrast | Minimal systemic absorption; low renal risk | Not restricted by eGFR alone |

These thresholds apply to all patients, not specifically to women on Evenity. Your doctor should order a serum creatinine or eGFR before your contrast scan if one has not been done in the past three months, regardless of what bone medications you take.

Older Women and Creatinine: A Sex-Specific Caution

This point matters especially for postmenopausal women, who make up essentially the entire clinical population for Evenity. Serum creatinine alone underestimates kidney disease severity in older women because muscle mass declines with age and after menopause, lowering creatinine production. A creatinine that looks "normal" at 0.9 mg/dL in a 68-year-old woman may correspond to an eGFR below 60 mL/min/1.73m². The CKD-EPI 2021 equation, which is sex-neutral but adjusts for age, should always be used to calculate eGFR rather than relying on the raw creatinine number.

Request the calculated eGFR, not just the creatinine, from your provider before any contrast procedure.

Imaging Findings on Evenity: What Your Radiologist Should Know

Beyond the contrast question, radiologists reading your scan need to know you are on romosozumab because the drug produces visible changes in bone structure that can be misinterpreted.

Bone Density Changes on DEXA and CT

Romosozumab increases bone mineral density substantially. The FRAME trial showed a 13.3% increase in lumbar spine BMD and a 6.9% increase in total hip BMD at 12 months compared to placebo. On CT scans of the spine, this increased density can alter Hounsfield unit values and change how vertebral trabecular bone appears, which may affect automated bone density algorithms used in opportunistic CT screening.

Periosteal New Bone Formation

Romosozumab stimulates both bone formation and bone resorption suppression. On MRI, this can occasionally produce periosteal signal changes or cortical thickening that an uninformed radiologist might flag as a pathological process (infection, tumor, or stress reaction). Providing your medication list prevents an unnecessary diagnostic workup.

Atypical Femoral Fracture Risk on Long-Term Imaging

The FDA label for romosozumab carries a warning for atypical femoral fractures (AFFs), though these are more commonly associated with bisphosphonates used after completing the Evenity course. If you are transitioning from Evenity to a bisphosphonate and you have thigh or groin pain, an MRI or femoral X-ray to screen for AFF prodrome may be ordered. Your radiology team should know your full treatment history.

Cardiovascular Adverse Events: Why This Is Relevant to Contrast Imaging

Romosozumab carries an FDA black box warning for major adverse cardiovascular events (MACE), including myocardial infarction and stroke. In the ARCH trial, which compared romosozumab to alendronate in 4,093 postmenopausal women, the romosozumab group had a statistically higher rate of MACE (2.5% vs. 1.9% at 12 months, p=0.04). This led to the black box warning, and Evenity should not be initiated in women who have had a heart attack or stroke in the past year.

This cardiovascular risk is directly relevant to contrast imaging because:

1. Iodinated contrast agents carry a small but real risk of contrast reactions, including hemodynamic instability, in patients with underlying cardiac disease.
2. Women with cardiac comorbidities who are on romosozumab despite the warning (or who developed cardiac events during treatment) may need cardiac pre-clearance before contrast CT or catheterization.
3. The black box warning means your cardiologist and your osteoporosis prescriber should be in communication if you require any contrast-enhanced cardiac imaging.

The decision framework for a postmenopausal woman on Evenity who needs contrast imaging should therefore run through three parallel checks: (a) renal function assessment (eGFR ≥30), (b) cardiovascular history review (no recent MI/stroke), and (c) notification of both the radiologist and the Evenity prescriber before scheduling. None of these checks involve a direct pharmacokinetic interaction between romosozumab and contrast agents, but all three are clinically necessary.

Can You Drink Alcohol on Evenity?

There is no direct pharmacokinetic interaction between romosozumab and alcohol. Romosozumab is a monoclonal antibody and is not metabolized by the liver enzymes that alcohol affects. The FDA label lists no alcohol restriction.

However, alcohol is independently harmful to bone. Regular alcohol consumption, typically defined in research as more than one drink per day in women, is associated with reduced bone mineral density and increased fracture risk. A 2022 meta-analysis in Osteoporosis International found that high alcohol intake (more than two drinks per day) was associated with a 28% increased risk of hip fracture in women. Drinking heavily while undergoing expensive monthly injections intended to rebuild bone works directly against the treatment goal.

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) recommends limiting alcohol to no more than two drinks per day for bone health, and many bone specialists counsel one drink or fewer.

Romosozumab does not prevent alcohol from damaging bone. Your 12 months of Evenity injections will be less effective if alcohol use is reducing the bone formation you are working to achieve.

Life-Stage Guide: Who Gets Evenity and How That Changes the Imaging Question

Postmenopausal Women (Primary Indication)

Evenity is FDA-approved specifically for postmenopausal women with osteoporosis at high fracture risk, defined as a prior osteoporotic fracture, a DEXA T-score at or below -2.5, or multiple clinical risk factors. This is the population in whom virtually all clinical trial data was collected.

Postmenopausal women often have other comorbidities (cardiovascular disease, chronic kidney disease, diabetes) that directly affect contrast imaging eligibility. The average age of women enrolled in FRAME was 71 years. Renal function declines with age, so eGFR screening before contrast is especially important in this group.

Perimenopausal Women

Evenity is not approved for perimenopausal women with premenopausal estrogen levels. Bone loss accelerates sharply in the first two to five years after the final menstrual period, but the fracture risk threshold that justifies Evenity typically is not reached until years after menopause. If you are perimenopausal and being screened or monitored with imaging, contrast is unlikely to be part of your bone-specific workup, though it may be used for other indications.

Reproductive-Age Women and Women with PCOS

Osteoporosis requiring Evenity is extremely uncommon in reproductive-age women. However, certain conditions affecting younger women, including anorexia nervosa, premature ovarian insufficiency (POI), and glucocorticoid-dependent conditions, can cause severe bone loss early in life. Women with premature ovarian insufficiency have estrogen deficiency comparable to natural menopause and are at elevated fracture risk, though romosozumab has not been studied in this specific group. If you are a younger woman with POI or severe glucocorticoid-induced osteoporosis and your physician is considering romosozumab off-label, the contrast imaging guidance above still applies, and pregnancy must be ruled out first (see section below).

Women with PCOS generally have normal or above-average bone density due to higher androgen levels and often higher body weight, so Evenity is rarely relevant in this population unless there are co-existing risk factors.

Pregnancy, Lactation, and Contraception: Required Reading

Romosozumab is contraindicated in pregnancy.

This is not a precautionary statement. Animal studies with romosozumab showed skeletal abnormalities in offspring at doses lower than the human therapeutic dose. The FDA label states that romosozumab may cause fetal harm when administered to a pregnant woman. The drug has not been studied in human pregnancies, and given its mechanism of action on bone morphogenetic signaling during fetal skeletal development, the theoretical risk is serious.

What This Means Practically

Evenity is indicated for postmenopausal women, so pregnancy should not be biologically possible for the primary intended population. However:

• Women with surgical menopause at a younger age, or women with POI being considered for off-label use, may still have a theoretical need for contraception if any residual ovarian function exists.
• If you are premenopausal and being considered for romosozumab for any reason, reliable contraception is required during the entire 12-month treatment course and for a reasonable washout period afterward. The label does not specify a defined post-treatment contraception window, but given the drug's half-life of approximately 6.4 days and clinical convention for monoclonal antibodies, most specialists counsel at least five half-lives (approximately 32 days) as a minimum, though some centers use 90 days out of caution.

Lactation

No human data on romosozumab transfer into breast milk exists. The drug is a large monoclonal antibody (136 kDa), and large-molecule drugs generally transfer into breast milk at very low levels due to molecular size. Oral bioavailability of ingested monoclonal antibodies in a nursing infant is also extremely low due to proteolytic degradation in the infant gut. However, because human data are absent and the drug may affect infant bone development, the FDA label advises against use during breastfeeding.

The practical population overlap here is minimal: a breastfeeding woman is unlikely to also meet criteria for romosozumab. If you are postpartum and breastfeeding and have unusually severe bone loss (pregnancy and lactation-associated osteoporosis is a real and underdiagnosed condition), the first-line treatment is not romosozumab. Discuss options with a bone specialist.

Evidence Gap Acknowledgment

No randomized trial data exists for romosozumab in pregnant or lactating women, and none is expected given the risk profile. All pregnancy and lactation guidance for this drug is based on animal data, pharmacokinetic modeling, and regulatory extrapolation. This is an area of genuine evidence limitation that you deserve to know about.

Other Drug Interactions Worth Knowing

Romosozumab has a minimal traditional drug-drug interaction profile because it is not metabolized by CYP450 enzymes and does not significantly affect them. The FDA label identifies no formal DDI studies as showing clinically relevant interactions.

Practically, the drugs most commonly used alongside Evenity are:

• Calcium and vitamin D supplements: Required as co-administration during Evenity therapy. The FRAME trial protocol required all participants to take at least 500 mg calcium and 800 IU vitamin D daily. No interaction between supplementation and contrast agents exists.
• Sequential bisphosphonates: After completing 12 months of Evenity, most women transition to an antiresorptive (typically alendronate or zoledronic acid) to maintain the bone gains. Neither bisphosphonates nor Evenity interact with contrast dye pharmacokinetically.
• Hormone therapy (HT): Some postmenopausal women receiving HT for menopausal symptom management may also be on Evenity for bone protection. No interaction between HT and romosozumab has been documented in the label or in published pharmacokinetic studies. ACOG Practice Bulletin No. 141 on osteoporosis notes that while estrogen protects bone, it is not typically used as a sole osteoporosis treatment in women at high fracture risk, making combination with bone-specific agents like Evenity a clinical reality.
• Glucocorticoids: Chronic steroid use is a driver of secondary osteoporosis. No pharmacokinetic interaction with romosozumab exists, but the cardiovascular risks of chronic steroid use add to the already elevated MACE risk from Evenity itself, which is a clinical consideration your prescriber should weigh.

Who This Drug Is Right For, and Who Should Think Carefully

Likely Right For

• Postmenopausal women with a confirmed vertebral or hip fracture and a T-score at or below -2.5
• Postmenopausal women at very high fracture risk who have tried or cannot tolerate bisphosphonates
• Women who need rapid bone density gains (Evenity has the fastest BMD increment of any approved osteoporosis therapy in its 12-month window)
• Women whose fracture risk is high enough that the cardiovascular risk from Evenity is outweighed by the fracture prevention benefit, as assessed by a specialist

Think Carefully If You

• Have had a myocardial infarction or stroke in the past 12 months (black box contraindication)
• Have severe chronic kidney disease (eGFR <30), which also makes contrast imaging high-risk
• Are premenopausal without confirmed severe bone disease and a clear clinical indication
• Have a history of osteonecrosis of the jaw or poorly controlled dental disease (ONJ risk, same as with bisphosphonates and denosumab)
• Cannot commit to the 12-month injection schedule, since stopping early forfeits much of the benefit and requires immediate transition to an antiresorptive to prevent rapid bone loss rebound

Before Your Contrast Scan: A Practical Checklist

If you are on Evenity and your doctor has ordered a contrast-enhanced CT or MRI, go through this list before your appointment:

1. Tell your radiologist and radiology nurse you are on romosozumab (Evenity). Bring the medication name and dose.
2. Confirm your eGFR has been checked within the past three months. If not, ask your primary care provider or Evenity prescriber to order a basic metabolic panel before the scan.
3. If your eGFR is <30 mL/min/1.73m², contact both your prescribing physician and the radiology department before proceeding with contrast.
4. If you have had any cardiac event in the past 12 months, notify both teams so contrast-related hemodynamic risks can be assessed.
5. Arrive well hydrated. Adequate hydration before iodinated contrast is standard practice to reduce PC-AKI risk for any patient.
6. Ask the radiologist to note your romosozumab therapy in the report, so any bone structural findings are interpreted with appropriate context.

The American College of Radiology's contrast media guidelines provide the institutional framework that radiology departments follow, and your prescriber can reference these if there are questions about the pre-scan workup.